Sobi
- Company typePublic
- Founded1991
- HeadquartersCambridge, United Kingdom
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Sobi firmographics
Firmographics- Name
- Sobi
- Legal name
- Swedish Orphan Biovitrum AB (publ)
- Website
- https://sobi-uk.co.uk
- Company type
- Public
- Founded year
- 1991
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
Sobi industry classification
Industry- Product category
- Specialty Biopharmaceuticals for Rare Diseases
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics) (HLAAAAAL)
Keywords
Where Sobi is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Sobi business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain, Infrastructure
Revenue model
- Pharmaceutical product sales: Revenue generated from sales of specialty rare disease medications across hematology, immunology, and specialty care therapeutic areas
- Licensing and royalty arrangements: Sobi holds exclusive commercialization rights outside the US for pegcetacoplan (Aspaveli/EMPAVELI) from partnership with Apellis Pharmaceuticals
Go-to-market motion1 record
Distribution channels4 records
Marketing channels4 records
Sobi product offering
Product offeringCore offering
Sobi develops, manufactures, and commercializes specialty biopharmaceutical products for rare diseases spanning haematology, immunology, and specialty care. Its marketed portfolio includes Aspaveli/EMPAVELI, Doptelet, Gamifant, Vonjo, Altuvoct, and Tryngolza, sold to healthcare providers, hospitals, and national health systems globally. The company supplements internal R&D with licensing and acquisition deals (e.g., Apellis co-development for pegcetacoplan and the Arthrosi Therapeutics acquisition for pozdeutinurad).
Product overview
Sobi is a global biopharmaceutical company focused on rare diseases, with a portfolio of marketed products spanning haematology (Altuvoct for haemophilia A, Vonjo for myelofibrosis), immunology (Gamifant for HLH, Aspaveli for PNH and kidney diseases), and specialty care (Doptelet for ITP, Tryngolza for hypertriglyceridemia). The company operates a platform-plus-pipeline model with six strategic products forming the core commercial portfolio, while advancing multiple late-stage pipeline candidates including NASP for gout and pozdeutinurad for gout acquired from Arthrosi Therapeutics. Sobi distributes products across Europe, North America, and Asia Pacific through direct commercialization and strategic partnerships.
Differentiator
Problem solved
Functional benefit
Brands
- ASPAVELI enFuse: Aspaveli with enFuse On-Body Delivery System for subcutaneous administration
- Unite4Rare
Products and services
- Aspaveli (pegcetacoplan) Subcutaneous C3 inhibitor for treating paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy (C3G), and primary immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN); approved in the EU and Canada.
- Doptelet (avatrombopag) Thrombopoietin receptor agonist for treating immune thrombocytopenia (ITP); stimulates platelet production in patients with chronic ITP.
- Gamifant (emapalumab) Monoclonal antibody targeting interferon-gamma for treating primary haemophagocytic lymphohistiocytosis (HLH); currently in Phase 2a for interferon-gamma-driven sepsis.
- Vonjo (pacritinib) JAK2 inhibitor for treating myelofibrosis, a rare bone marrow disorder characterized by abnormal blood cell production and fibrosis.
- Altuvoct (efanesoctocog alfa) Extended half-life recombinant factor VIII therapy for haemophilia A, offering protection with prolonged intervals between infusions.
- Tryngolza (olezarsen) APOC3-targeting antisense oligonucleotide for severe hypertriglyceridemia; Phase 3 showed 85% reduction in acute pancreatitis risk and 66% triglyceride reduction.
- NASP (nanoencapsulated sirolimus plus pegadricase) Investigational combination therapy for uncontrolled gout using nanoencapsulation technology; currently in regulatory review following FDA Complete Response Letter.
- Pozdeutinurad (AR882) Once-daily oral URAT1 inhibitor acquired via Arthrosi Therapeutics for gout; in Phase 3 trials for progressive and tophaceous gout.
Quantifiable outcome
- 85% reduction in acute pancreatitis risk with Tryngolza in severe hypertriglyceridemia patients
- +3 more outcomes
Companies that use Sobi
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles1 record
Sobi technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature3 records
Sobi partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered strategic, core and minor.
- Enable InjectionsstrategicEnable Injections received CE Certification for its enFuse On-Body Delivery System for use with Aspaveli, commercialized as ASPAVELI enFuse and distributed by Sobi across EU. Strategic partnership includes regulatory clearances in Saudi Arabia, Brazil, South Korea, and Canada.
- Arthrosi TherapeuticscoreSobi completed acquisition of Arthrosi Therapeutics in February 2026, adding pozdeutinurad (AR882), an investigational URAT1 inhibitor in Phase 3 trials for gout, to Sobi's pipeline. The acquisition strengthens Sobi's gout franchise for patients sub-optimally treated or unresponsive to first-line urate-lowering therapies. Deal valued at up to $1.5 billion including $950M upfront and up to $550M milestone payments.
- Apellis PharmaceuticalscoreSobi and Apellis hold global co-development rights for subcutaneous pegcetacoplan, with Sobi holding exclusive commercialization rights outside the United States. Products include Aspaveli/EMPAVELI for PNH, C3G, and primary IC-MPGN.
- Hellenic Institute for the Study of Sepsis (HISS)minorCollaboration with HISS on Phase 2a EMBRACE study evaluating emapalumab in interferon-gamma-driven sepsis, with 75 patients enrolled across 24 sites in Greece.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Sobi competitors and assessment
Company assessmentDirect peers
- BioMarin Pharmaceutical: BioMarin is a rare-disease-focused specialty biopharma with franchises in hematology, enzyme replacement, and rare metabolic disorders. It is the most direct structural peer to Sobi, with comparable revenue scale, orphan-drug commercial model, and pipeline-driven growth strategy.
- Vertex Pharmaceuticals: Vertex is a high-growth specialty biopharma anchored by rare-disease franchises (cystic fibrosis, sickle cell) and expanding into specialty care areas. Comparable to Sobi in revenue magnitude, focus on small-population indications, and pipeline-led top-line growth.
- Alexion (AstraZeneca Rare Disease): Alexion pioneered the rare-disease commercial model with Soliris/Ultomiris in PNH and complement-mediated diseases, overlapping directly with Sobi's Aspaveli/EMPAVELI in PNH and C3G/IC-MPGN. AstraZeneca's ownership gives it global scale advantages Sobi must match.
- Alnylam Pharmaceuticals: Alnylam is the leader in RNA interference therapeutics, including an APOC3-targeting siRNA for cardiovascular metabolic indications that overlaps with Sobi's Tryngolza (APOC3 antisense). It is a direct scientific and commercial competitor in cardiometabolic rare and specialty disease.
- Ionis Pharmaceuticals: Ionis developed the antisense oligonucleotide platform underlying Tryngolza (olezarsen) and is a key licensor/partner for Sobi's cardiometabolic franchise. Comparable in technology platform, rare-disease pipeline focus, and reliance on partnership-driven commercialization.
- Apellis Pharmaceuticals: Apellis is Sobi's co-development partner for pegcetacoplan (Empaveli/Aspaveli) and directly overlaps on PNH and C3G/IC-MPGN indications in the US. As a complement-inhibitor pure-play, it is both collaborator and primary US competitor to Sobi's pegcetacoplan franchise.
- Kyowa Kirin: Kyowa Kirin is a Japan-headquartered specialty biopharma focused on rare diseases and specialty care, with commercial overlap in hematology, immunology, and rare metabolic disorders. Comparable business model and reliance on regulatory exclusivity and global partnerships for growth.
- Recordati Rare Diseases: Recordati Rare Diseases is a European specialty pharma with a portfolio of rare-disease treatments across metabolic, endocrine, and hematology indications. Comparable in size, European commercial orientation, and focus on underserved rare-disease populations.
Broad incumbents
- Sanofi (Genzyme): Sanofi, through its Genzyme unit, is one of the largest rare-disease franchises globally with overlapping presence in hematology, immunology, and rare metabolic conditions. It competes broadly with Sobi across multiple therapeutic areas with much larger scale and resources.
- Takeda Pharmaceutical: Takeda is a global specialty biopharma with a substantial rare-disease and hematology franchise (post-Shire acquisition) and competes with Sobi in hemophilia, immunology, and rare metabolic disorders. Operates at far larger scale but in overlapping indications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Sobi social profiles
Digital presenceSobi financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sobi leadership team
Management profileNumber of profiles
Profiles2 records
Sobi subsidiaries and ownership
Company hierarchySubsidiaries2 records
Sobi funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sobi M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sobi
What does Sobi do?
Sobi develops, manufactures, and commercializes specialty biopharmaceutical products for rare diseases spanning haematology, immunology, and specialty care. Its marketed portfolio includes Aspaveli/EMPAVELI, Doptelet, Gamifant, Vonjo, Altuvoct, and Tryngolza, sold to healthcare providers, hospitals, and national health systems globally. The company supplements internal R&D with licensing and acquisition deals (e.g., Apellis co-development for pegcetacoplan and the Arthrosi Therapeutics acquisition for pozdeutinurad).
Is Sobi a public or private company?
Sobi is a public company. It is classified as public and is currently operating.
When was Sobi founded?
Sobi was founded in 1991. It employs 1,001 to 5,000 people.
Where is Sobi based?
Sobi is headquartered in Cambridge, United Kingdom, in the Europe region.
How does Sobi make money?
Two revenue lines are on record. Pharmaceutical product sales are the primary driver. The others are licensing and royalty arrangements.
Who are Sobi's main competitors?
Direct peers on record are BioMarin Pharmaceutical, Vertex Pharmaceuticals, Alexion (AstraZeneca Rare Disease), Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Kyowa Kirin and Recordati Rare Diseases. Broad incumbents are Sanofi (Genzyme) and Takeda Pharmaceutical.
Does Sobi have an API?
No public API is recorded for Sobi.
What industry is Sobi in?
Sobi's product category is Specialty Biopharmaceuticals for Rare Diseases. Its primary akta.pro industry code is HLAAAAAL, Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics). Its NAICS code is 3254 and its SIC code is 2834.